CVR number 27299032
Industry 46.4610 Wholesale of pharmaceutical goods

NORDMEDICA A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  9.2% 8.4% 7.8% 3.7% 5.5%  
Credit score (0-100)  27 28 31 51 41  
Credit rating  BB BB BB BBB BBB  
Credit limit (kEUR)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kEUR) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  888 1,002 635 588 153  
EBITDA  888 1,002 635 588 153  
EBIT  691 1,002 635 588 153  
Pre-tax profit (PTP)  792.7 1,029.1 965.4 1,047.3 801.0  
Net earnings  608.6 784.6 723.2 765.9 616.2  
Pre-tax profit without non-rec. items  793 1,029 965 1,047 801  
 
See the entire income statement

Balance sheet (kEUR) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  11,074 11,845 12,549 13,283 897  
Interest-bearing liabilities  291 294 305 320 0.0  
Balance sheet total (assets)  11,383 12,202 13,103 13,871 998  
Net Debt  238 254 274 309 -20.2  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  888 1,002 635 588 153  
Gross profit growth  -29.2% 12.8% -36.6% -7.4% -74.0%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  11,383 12,202 13,103 13,871 998  
Balance sheet change%  4.9% 7.2% 7.4% 5.9% -92.8%  
Added value  887.8 1,001.7 634.8 587.5 152.7  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -393 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  5.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  77.9% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  7.2% 8.8% 7.8% 8.0% 11.1%  
ROI %  7.2% 8.8% 7.9% 8.1% 11.4%  
ROE %  5.7% 6.8% 5.9% 5.9% 8.7%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  97.3% 97.1% 95.8% 95.8% 89.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  26.8% 25.3% 43.1% 52.6% -13.2%  
Gearing %  2.6% 2.5% 2.4% 2.4% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  1.7% 1.7% 6.5% 8.7% 16.4%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  36.9 36.6 25.2 23.5 9.7  
Current Ratio  36.9 36.6 25.2 23.5 9.7  
Cash and cash equivalent  53.4 40.1 30.9 11.1 20.2  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  11,074.4 11,868.3 12,582.7 13,207.3 879.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 588 153  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 588 153  
EBIT / employee  0 0 0 588 153  
Net earnings / employee  0 0 0 766 616